Access to chemical matter is a major bottleneck in drug discovery. Established industry standards and screening methods often fail to deliver molecular starting points for drug design. Despite accumulating large collections of compounds and screening millions of molecules, the industry struggles to unlock chemical matter.

Serghei Glinca founded CrystalsFirst as a spin-out from Prof. Dr Gerhard Klebe's group at the University of Marburg, Germany, leveraging the lab's recently developed Smart Soak technology.

In this episode of BioInnovation Spotlight, Serghei talks about how CrystalsFirst aims to revolutionize the drug discovery process by targeting previously undruggable targets using the power of their protein crystallization technology and data-driven modelling.